Ascentage Pharma (6855.HK) announced today that the company has been included in the Shanghai Stock Exchange's 'First Batch of List of Stocks Newly Transferred to Shanghai-Hong Kong Stock Connect'.

The adjustment will come into effect on March 13, 2023 (Monday). Previously, Ascentage Pharma had been included in the Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect. After this adjustment, the company will become a 'double-included' stock for the Hong Kong Stock Connect of the Shanghai and Shenzhen stock exchanges.

The Shanghai Stock Exchange issued the 'Notice on the First Adjustment of the Hong Kong Stock Connect Standards under the Shanghai-Hong Kong Stock Connect after the Expansion of the Shanghai-Hong Kong Stock Connect', which shows that the adjustment stems from the 'Implementation Measures for the Shanghai-Hong Kong Stock Connect Business of the Shanghai Stock Exchange (Revised in 2023)> and the Notice on Related Matters (Shang Zheng Fa [2023] No. 53). Previously, the China Securities Regulatory Commission and the Hong Kong Securities Regulatory Commission issued a joint announcement to expand the scope of stock interconnection targets, continue to promote the further optimization and improvement of the interconnection mechanism, and further enhance the level of two-way opening up of my country's capital market.

This is the first adjustment after the expansion of the scope of Shanghai-Hong Kong Stock Connect stocks, and it also represents Ascentage Pharma's further opening of channels for institutional investors in mainland China after being included in the Shenzhen-Hong Kong Stock Connect stock list on December 28, 2020.

According to the newly adjusted standards, eligible constituent stocks of the Hang Seng Composite Small Cap Index will be included in the Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect. The Hang Seng Composite Small Cap Index has certain requirements for stock stability and liquidity. To meet these requirements, the company's own product pipeline strength, performance growth and market prospects must stand the test.

Becoming the standard of Shanghai-Hong Kong Stock Connect is an affirmation of Ascentage Pharma's popularity and influence in the international capital market, and it is also expected to attract more investors to participate, which will have a positive effect on liquidity and liquidity.

As the first stock of original small molecule new drugs in the Hong Kong stock market, Ascentage Pharma has always adhered to the two strategies of 'original innovation' and 'global innovation' since its listing, and achieved the launch of the first commercial product, constantly climbing the peak of corporate development. At the beginning of this year, Ascentage Pharma has achieved several major milestones, demonstrating the company's remarkable innovative R&D, commercialization capabilities and the high recognition of the company by the capital market. The company's first marketed product, Nalike, was included in the National Medical Insurance List in January this year, and as a representative of major domestic innovative drugs, it was highlighted in the official announcement documents of the Medical Insurance Bureau. On March 1, Nelike issued the first batch of 'medical insurance prescriptions', marking the practical improvement of its drug accessibility and affordability. In addition, Ascentage Pharma also successfully placed about HK$550 million in public placement of new shares in January, which shows the capital market's recognition of the company's investment value and high recognition of its future development.

Dr. Yang Dajun, Chairman and CEO of Ascentage Pharma, said: 'Ascentage Pharma, as the first batch of 18A companies newly added to the Shanghai-Hong Kong Stock Connect after the new policy, is a milestone in the development of the company's capital market and fully reflects the This has confirmed the capital market's recognition and confidence in the company's innovation strength and development prospects. The company is expected to further expand the investor base and improve the liquidity of stocks, and promote good performance in the capital market. In the future, we will continue to improve research and development capabilities and further enhance the durability of listed products. The accessibility of LIKE accelerates the progress of clinical development of the company's product pipeline, and truly fulfills the mission of 'solving the unmet clinical needs of patients in China and even the world', so as to benefit more patients and create more value for shareholders. '

Contact:

Tel 86-512-85557777

(C) 2023 Electronic News Publishing, source ENP Newswire